Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 , at 9:00 a.m. PT in San Francisco. Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.) A live webcast will be available in the Investors section of the company's website at www.nuvalent.com , and archived for 30 days following the presentation. About Nuvalent Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastase
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Nuvalent Appoints Grant Bogle to Board of DirectorsPR Newswire
- Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare ConferencePR Newswire
- Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $115.00 price target on the stock.MarketBeat
- Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial ResultsPR Newswire
NUVL
Earnings
- 11/12/24 - Miss
NUVL
Sec Filings
- 12/26/24 - Form 4
- 12/20/24 - Form 4
- 12/18/24 - Form 4
- NUVL's page on the SEC website